News

Stock Movers: Novo Nordisk, Palo Alto, Union Pacific

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Instant View: Reaction to new Novo Nordisk CEO, profit warning

Novo Nordisk on Tuesday appointed insider Mike Doustdar as its new chief executive after the Danish obesity drug maker cut ...

Novo Nordisk: Is This An Overreaction Or The End Of The GLP-1 Fairy Tale?

Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...

Novo Nordisk shares fall 20% after company names new CEO and lowers its financial outlook

Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...
Opinion

Novo Nordisk’s Weight Loss Lesson

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

New tariffs could raise prices of Ozempic, Wegovy

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...

Eli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.

A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...

Novo Nordisk stock crashes after company cuts sales, profit outlook on weight-loss drug competition

Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...